Correlates of Immunity to Filovirus Infection by Bradfute, Steven B. & Bavari, Sina
Viruses 2011, 3, 982-1000; doi:10.3390/v3070982 
 
viruses
ISSN 1999-4915 
www.mdpi.com/journal/viruses 
Review 
Correlates of Immunity to Filovirus Infection 
Steven B. Bradfute and Sina Bavari * 
United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort 
Detrick, Maryland, MD 21702, USA; E-Mail: steven.bradfute@us.army.mil 
*  Author to whom correspondence should be addressed; E-Mail: sina.bavari@amedd.army.mil;  
Tel.: +1-301-619-4246. 
Received: 14 April 2011; in revised form: 14 June 2011 / Accepted: 16 June 2011 /  
Published: 27 June 2011 
 
Abstract: Filoviruses can cause severe, often fatal hemorrhagic fever in humans. Recent 
advances in vaccine and therapeutic drug development have provided encouraging data 
concerning treatment of these infections. However, relatively little is known about immune 
responses  in  fatal  versus  non-fatal  filovirus  infection.  This  review  summarizes  the 
published  literature  on  correlates  of  immunity  to  filovirus  infection,  and  highlights 
deficiencies in our knowledge on this topic. It is likely that there are several types of 
successful immune responses, depending on the type of filovirus, and the presence and 
timing of vaccination or drug treatment. 
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1. Introduction 
Filoviruses  are  enveloped,  single-stranded,  negative-sense  RNA  viruses  that  can  cause  lethal 
hemorrhagic  fever  [1].  Three  distinct  groups  of  filoviruses  have  been  described:  Ebolaviruses, 
marburgviruses,  and  the  newly  discovered  cuevaviruses.  There  are  five  currently  known 
ebolaviruses—Ebola  (EBOV,  previously  called  Zaire),  Sudan  (SUDV),  Bundibugyo  (BDBV),  Taï 
Forest (TAFV, previously called Côte d’Ivoire), and Reston (RESTV); two marburgviruses—Marburg 
(MARV) and Ravn (RAVV); and one cuevavirus, Lloviu (LLOV) [2]. EBOV and marburgviruses 
appear to have similar lethality in humans, with rates of approximately 70–90%. SUDV lethality in 
humans is ≈50%, and BDBV is ≈30%. No human deaths have been attributed to TAFV, RESTV, or 
LLOV. Filoviruses are endemic in Central Africa and the Philippines, and are NIAID Category A 
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Priority Pathogens due to their lethality, potential for misuse, and ability to be aerosolized. Bats are 
possible  reservoirs  for  filoviruses,  and  are  thought  to  spread  disease  to  humans  either  directly  or 
through infection of nonhuman primates (NHPs) and possibly swine [1,3–7].  
A number of vaccines have successfully protected NHPs from filovirus infection (reviewed in [8]). 
Additionally, anti-sense and RNA interference therapeutics against EBOV or MARV can be protective 
against NHP infection [9,10]. However, no treatment or vaccine has been proven to be effective in 
human filovirus infection.  
Wild-type  filoviruses  are  lethal  in  untreated  NHPs,  making  comparison  of  successful  versus 
unsuccessful immune responses difficult, due to a lack of a significant number of survivors. Wild-type 
filoviruses are generally not lethal in mice and guinea pigs, but there are lethal mouse-adapted (EBOV, 
RAVV) and guinea pig-adapted (EBOV, MARV, RAVV) models available [11–15]. Mice infected via 
the  subcutaneous  (s.c.)  route  with  mouse-adapted  EBOV  (ma-EBOV)  survive  infection,  whereas 
intraperitoneal (i.p.) infection is lethal [11]. Although it is not known why route of infection alters 
survival outcome, protection is correlated with differential cytokine expression, as described in the 
next section. Additionally, mice with decreased levels of CD45 expression (CD45
lo) are resistant to 
maEBOV infection, and this protection correlates with altered cytokine expression and a requirement 
for CD8+ T cells and IFN-gamma (see below) [16]. The use of lethal and non-lethal filovirus mouse 
models  allow  for  analysis  of  protective  immune  responses  without  therapeutic  treatment  or 
vaccination.  Correlates  of  immunity  to  filovirus  infection  have  also  been  studied  in  vaccination 
experiments in NHPs, mice, and guinea pigs. These studies have yielded results that suggest there are 
several ways the immune system can protect against filoviruses infection.  
This  review  aims  to  collate  the  available  published  data  and  summarize  what  is  known  about 
immune responses to filovirus infection, and to highlight areas for future research to close the gaps in 
knowledge on this topic.  
2. Discussion 
2.1. Cytokines  
Type  I  interferon  (IFN)  is  essential  in  controlling  filovirus  infection.  Adult,  immunocompetent 
wild-type mice are not susceptible to wild-type filovirus infection; however, inhibition of type I IFN 
(via knockout of the IFN alpha/beta receptor I, STAT1, or antibody-mediated depletion of IFN alpha 
and IFN beta) results in lethal infection with most wild-type filoviruses [17]. Mouse-adapted EBOV 
likely acquired its lethality in mice by mutations that abrogated mouse type I IFN responses [18]. 
Additionally, induction of type I IFN protects mice from otherwise lethal maEBOV infection [19,20]. 
Treatment  of  NHPs  with  IFN-alpha2  prolongs  time-to-death  in  EBOV-  or  MARV-infected  NHP 
[21,22]. Although type I IFN is sometimes elevated in lethal infection (see below), it is often detected 
later in infection, perhaps too late to be effective. On a molecular level, certain filoviral genes (VP35, 
VP24, and VP40) inhibit type I IFN function through a variety of mechanisms [23–38]. This topic is 
more thoroughly reviewed by [39]. 
Due to the sporadic nature of filovirus outbreaks, and the remote locations where the viruses are 
endemic, it is difficult to obtain samples from infected humans. Nonetheless, a few studies of cytokine Viruses 2011, 3                         
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expression in human fatal and non-fatal EBOV and SUDV infection have been published. It is very 
difficult  to  directly  compare  cytokine  responses  between  survivors  and  non-survivors  in  human 
infections.  Pre-existing  endemic  infections  (such  as  HIV  or  parasites)  could  impact  survival  after 
filovirus infection, but these variables are often not analyzed. Most published studies have compared 
samples from these groups based on time of symptom onset. Although this is a reasonable comparison, 
it does not account for the possibility that survivors or non-survivors may have differences in immune 
responses prior to symptom onset. For example, survivors may have more robust type I IFN responses 
before symptom onset compared to non-survivors. Sampling of cytokine expression based on onset of 
symptoms would then fail to detect early responses that may control the overall outcome of infection. 
Therefore, time of infection is a more accurate basis to compare immune responses between survivors 
and non-survivors. Of course, it is nearly impossible to determine time of infection in human outbreak 
settings, highlighting one advantage of using animal models to analyze immune responses. The human 
cytokine data are vital and informative, but must be analyzed with these limitations in mind. 
Although  some  of the human  data  are  contradictory,  the limited  data suggest  that fatal EBOV 
infection is correlated with an increase in pro-inflammatory cytokines (such as tumor necrosis factor 
(TNF)-alpha,  IFN-gamma,  IL-6,  IL-8,  IL-1  beta,  MIP-1  alpha,  MIP-1  beta,  MCP1,  etc.),  whereas  
non-fatal infection lacks this explosion of cytokine release [40–43]. IL-10 production is also elevated 
during lethal EBOV infection, possibly due to attempts to dampen the rampant inflammatory response 
[44]. Interestingly, early and late IL-10 production is decreased in maEBOV-resistant CD45
lo mice 
compared  to  wild-type  mice,  suggesting  that  temporal  regulation  of  IL-10  may  be  important  in 
controlling filovirus infection [16]. NHP studies of lethal EBOV [45–47] and RESTV [48] infection 
confirm the increase in pro-inflammatory cytokine production. Possible asymptomatic EBOV infection 
in humans is correlated with strong but transient early pro-inflammatory cytokine production [49,50], 
again  suggesting  that  temporal  control  of  cytokine  expression  is  important  in  controlling  EBOV 
infection.  Increased  type  I  IFN  and  TNF-alpha  concentrations  also  correlated  with  fatal  MARV 
infection in NHPs [51], and neutralization of TNF-alpha with antibody improved survival of guinea 
pigs after MARV infection [52]. Notably, TNF-alpha and IFN-gamma are not elevated in fatal human 
SUDV  infections  as  they  are  in  fatal  human  EBOV  infections,  suggesting  possible  differences  in 
immune responses to different filovirus species [53,54]. 
Filovirus  mouse  models  are  useful  for  immune  correlate  studies,  as  both  lethal  and  non-lethal 
models  exist.  Mice  infected  with  lethal  (mouse-adapted)  RAVV  generated  higher  levels  of  
pro-inflammatory cytokines and chemokines (such as IFN-gamma, IL-5, IL-12, MCP-1, MIG, and 
IFN-alpha) than mice infected with non-lethal (wild-type) RAVV [15]. Mice lethally infected with 
maEBOV (i.p. infection) generated higher TNF-alpha and MCP-1 levels, but lower IFN-gamma and 
IFN-alpha,  compared  to  non-lethal  (s.c.)  infection  [55].  Mice  genetically  resistant  to  maEBOV 
infection (CD45
lo mice), require IFN-gamma for protection [16]. Similarly, IFN-gamma is required for 
successful virus-like particle (VLP) vaccination against maEBOV in wild-type mice [56].  
Together,  these  data  suggest  that  temporal  regulation  of  cytokine  production  is  important  in 
controlling filovirus infection. One model proposes that inhibition of early type I IFN responses, but  
an  increase  in  other  pro-inflammatory  cytokine/chemokine  expression,  results  in  fatal  filoviral 
infection [23]. In this model, belated type I IFN responses would result in delayed adaptive immune 
responses and decreased antiviral innate responses; the later deluge of pro-inflammatory cytokines, Viruses 2011, 3                         
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such  as  TNF-alpha,  would  contribute  to  organ  damage  and  vascular  leakage  in  lethal  infection. 
However,  a  tightly  controlled,  transient  early  type  I  IFN  and  pro-inflammatory  cytokine  response 
would induce protective antiviral innate and adaptive immune responses. It is important to note that 
there are some contradictions in cytokine levels reported between SUDV and EBOV, suggesting that 
direct comparison across different filoviruses may not be possible [40–43,53,54]. It is also notable that 
induction of massive pro-inflammatory cytokine expression occurs in human infections, as well as 
NHP and mouse models of filovirus infections, revealing the usefulness of animal models to study 
human disease.  
2.2. Lymphocyte Apoptosis 
Widespread  and  profound  lymphocyte  apoptosis  is  found  in  fatal,  but  not  non-fatal,  filovirus 
infection. However, lymphocytes are not productively infected with filoviruses. Lymphocyte death 
was first discovered by microscopy in the organs of human patients that succumbed to EBOV infection 
[57,58]. Apoptosis in peripheral blood cells, as measured by DNA cleavage in PBMC, was found in 
fatal, but non non-fatal, EBOV infection in humans [40]. NHPs or mice lethally infected with EBOV 
or  MARV  also  display  lymphocyte  apoptosis  (as  measured  by  conventional  microscopy,  electron 
microscopy, or TUNEL staining) in multiple tissues [15,45,59–61]. EBOV lymphocyte apoptosis has 
been found to correlate with increased Fas/FasL and/or TRAIL expression [42,45,46,62]. Additionally, 
transgenic mice that survive EBOV infection do not have profound lymphocyte apoptosis, whereas 
those that succumb to infection do [16]. 
Findings such as these led to a hypothesis that filovirus-induced bystander lymphocyte apoptosis 
results  in  the  elimination  of  adaptive  immune  responses  and  subsequent  overwhelming  viral 
pathogenesis [40,45,61,63]. However, ensuing experiments demonstrated that lethally infected mice 
generated a maEBOV-specific CD8+ T cell response despite the presence of T cell apoptosis [60]. 
This response correlated with the appearance of lymphoblasts, rebound of peripheral blood CD8+ T 
cell  numbers,  and  expression  of  activation  markers  (increased  CD44  and  decreased  CD62L  and 
CD127). Notably, adoptive transfer of purified CD8+ T cells from lethally infected mice protected 
naïve  recipients  from  subsequent  maEBOV  infection  [60].  This  occurred  despite  concurrent 
lymphocyte apoptosis in lymphoid organs. The appearance of lymphoblasts, increased lymphocyte 
CD44  expression,  and  late-stage  increase  in  peripheral  lymphocyte  counts  have  been  reported  in 
human and/or NHP EBOV studies [45,54,62,64,65]. Additionally, specific antibody responses can be 
found in many EBOV and SUDV lethally-infected humans [40,66–68] (Table 1). These data suggest 
that a functional and specific CD8+ T cell (and perhaps B cell) response can be generated in lethal 
infection, despite massive bystander lymphocyte apoptosis. 
Transgenic and knockout mice were used to directly test whether lymphocyte apoptosis is important 
for lethal filovirus infection. maEBOV-induced lymphocyte apoptosis was shown to occur via both the 
extrinsic (death receptor) and intrinsic apoptotic pathways in lethally infected mice [69]. However, the 
elimination  of  maEBOV-induced  lymphocyte  apoptosis  (in  bcl-2  transgenic  mice)  did  not  protect 
animals from lethal infection, suggesting that lymphocyte apoptosis is not a major factor in EBOV 
pathogenesis [69]. In fact, bcl-2 transgenic mice had higher viral titers and decreased CD8+ T-cell 
responses compared to wild-type mice. Viruses 2011, 3                         
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Table 1. Anti-ebolavirus antibodies in fatal human cases. The literature was surveyed for 
reports of anti-filovirus antibodies in the serum of lethally-infected human patients. Four 
studies were found, and are reported here. In each case, the lowest dilution of serum tested 
was 1:100. NR, not reported. 
Ebolavirus   IgM+  IgG+  Reference 
SUDV  2/3 (67%)  2/3 (67%)  [67] 
SUDV  NR  6/27 (22%)  [68] 
EBOV  3/7 (43%)  4/7 (57%)  [66] 
EBOV  1/3 (33%)  0/3 (0%)  [40] 
       
Total SUDV  2/3 (67%)  8/30 (27%)   
Total EBOV  4/10 (40%)  4/10 (40%)   
Total Combined  6/13 (46%)  12/40 (30%)   
 
Together, these data suggest that EBOV-induced lymphocyte apoptosis does not abrogate adaptive 
immune responses, and is not required for pathogenesis. Why does it occur? It is possible that the high 
levels of pro-inflammatory cytokine expression late in lethal filovirus infection leads to bystander 
lymphocyte apoptosis, and is a byproduct of fatal infection but not a cause. Experiments conducted in 
an acute, non-lethal lymphocytic choriomeningitis (LCMV) infection mouse model have shown that 
both LCMV specific and non-specific CD8+ T cells undergo apoptosis during infection, despite a 
successful  CD8+  T-cell  response  [70,71].  Interestingly,  there  is  evidence  that  this  apoptosis  is 
mediated by type I IFN production [71]. Future experiments should focus on whether the apoptotic T 
and B cells in filovirus infection are filovirus-specific.  
2.3. B Cells and Antibody 
Antibody levels are generally thought to be low or absent in fatal filoviral infection, leading to  
the hypothesis that suppression of B cell responses and antibody production correlate with fatality. 
However, a review of the limited available literature (Table 1) shows that antibody responses are  
found in many fatal EBOV and SUDV human infections, at levels similar to those of some survivors 
[40,66–68]. These data suggest that antibody responses can be generated in lethal infection, and the 
mere presence or absence of antibody does not necessarily correlate with lethality. However, the data 
do not rule out the possibility that survivors generate more functional antibody than non-survivors. 
Successful vaccination against filovirus infection in NHPs generates a range of antibody titers, 
depending  on  the  vaccine  platform  [72–79];  most  platforms  do  not  generate  substantial  in  vitro 
neutralizing  antibody  titers.  Protection  against  EBOV  challenge  using  adenovirus-based  vaccines 
correlates with total antibody titers; all NHPs that generated a certain level of antibody titer were 
protected from challenge, whereas those having lower titers were only partially protected [80]. On the 
other  hand,  vaccination  of  NHPs  with  replication-competent  vesicular  stomatitis  Indiana  virus  
(VSV)-based filovirus vaccines generated low levels of antibody, but vaccination was protective when 
given  pre-  or  post-  infection  against  a  number  of  filoviruses  [81–86].  Virus-like  particle  (VLP) 
vaccines  generated  moderate  to  high  levels  of  antibody  in  NHPs,  along  with  moderate  levels  of 
neutralizing antibody, against MARV and EBOV [72,73]. B cells were required for protection against Viruses 2011, 3                         
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maEBOV in VLP-vaccinated mice, but this has not been tested in any other filovirus vaccine platform 
[87]. In an extreme example, vaccination against EBOV and SUDV protected NHPs against BDBV 
infection,  even  though  no  antibodies  against  BDBV  were  detected  [79].  While  these  findings  
must be confirmed, it appears that the antibody level required to protect against filovirus infection 
probably differs according to the vaccination platform and regimen, as well as the particular filovirus  
being tested.  
Transfer of IgG+ convalescent whole blood to EBOV-infected human patients protected 8/9 from 
lethal infection (compared to 20% survival in untreated patients) [88]. Although this study was not 
controlled, and the transfused patients received better care than the untreated patients, it did suggest the 
possibility that antibody could protect against filovirus infection. Passive transfer of whole sera or 
monoclonal antibodies have been shown to protect mice or guinea pigs from lethal EBOV or MARV 
infection [13,21,89–98]. Interestingly, passive transfer experiments showed that in vitro neutralizing 
antibody activity was not necessarily required for antibody-mediated protection of maEBOV infection 
in mice or MARV infection in guinea pigs [89,92,96]. Passive transfer of immune horse sera protected 
baboons from EBOV infection [97,99,100]; however, other studies in EBOV-infected macaques did 
not show protection with passive transfer of a monoclonal antibody, immune IgG, or convalescent 
whole blood [21,101,102]. These mixed results implore the initiation of additional studies to rescue 
NHP from filovirus infection by passive transfer of antibodies or immune sera.  
There  is  virtually  no  information  on  how  antibody  might  aid  in  protection  against  filovirus 
infection. As mentioned above, most successful vaccinations in NHP filovirus models do not generate 
in  vitro  neutralizing  antibodies,  and  neutralization  itself  is  not  required  for  protection  in  passive 
transfer experiments. There is little to no information on complement fixation, ADCC, or opsonization 
capabilities  of  antibodies  generated  in  vaccinated  or  surviving  animals  or  humans  in  response  to 
filovirus infections. Measurement of antibody titers against filovirus antigen does not measure how 
functional  the  antibody  is;  many  pathogens  (such  as  HIV-1)  induce  antibody  production  against  
non-protective epitopes. Therefore, we really have no idea how antibody might protect against filovirus 
infection. More thorough investigations on functionality of antibody would likely address the varied 
results  obtained  from  the  vaccination  studies  listed  above.  It  is  likely  that  antibodies  induced  in 
different ways will act through different mechanisms to induce protection; therefore, it is important to 
note that failure of a particular antibody preparation to protect against filovirus infection does not 
necessarily mean that antibody is not a potential therapeutic regimen. Additionally, further work to 
establish  the  importance  and  requirement  for  antibodies  in  protection  against  different  filoviruses  
is warranted. 
2.4. T Cells 
Humans  that  survive  SUDV  infection  have  been  shown  to  generate  higher  percentages  of 
phenotypically activated (HLA-DR+) CD8+ T cells than non-survivors [54]. Similarly, CD45
lo mice 
are  resistant  to  maEBOV-induced  lethality,  and  generate  higher  percentages  of  phenotypically 
activated (CD44 high) CD8+, but not CD4+, T cells [16]. Depletion of CD8a+ T cells in these mice 
leads to lethal maEBOV infection. Viruses 2011, 3                         
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CD8+  T  cells  and  CD4+  T  cells  are  required  for  VLP  vaccine-mediated  protection  against 
maEBOV  in  mice  [87].  However,  depletion  of  CD8+  T  cells  during  VSV  vaccination  (but  not 
challenge) against maEBOV does not abrogate protection in mice [91]. CD8+ T cells are required for 
protection in mice infected s.c. with maEBOV, and this protection requires perforin, but not Fas or 
IFN-gamma  [103,104].  Vaccination  of  mice  with  Venezuelan  equine  encephalitis  virus  replicons 
(VRP)-based  vectors  generated  multiple  epitope-specific  CD8+  T  cells  that  were  protective  after 
expansion and subsequent adoptive transfer [105,106]. Similarly, mice infected with wild-type, non-
lethal RAVV generated epitope-specific CD8+ T cells; adoptive transfer of splenocytes from these 
mice, after expansion in vitro with peptide epitopes, protected recipient mice from subsequent mouse-
adapted RAVV infection [106].  
In NHP studies, different protective vaccination platforms generate various levels of CD4+ and/or 
CD8+ T-cell responses, ranging from non-existent to profound [73,74,76–79,107,108]. Vaccination 
with EBOV VLPs generated robust T-cell cytokine responses [73]. A DNA prime/adenovirus-GP1,2 
boost  (DNA/AdV)  vaccine  regimen  that  is  protective  against  EBOV  infection  in  NHPs  generated 
memory CD4+, but not CD8+, T cells that proliferated in vitro after stimulation with antigen [78]. 
CD8+  T-cell  IFN-gamma  responses  were,  however,  present  after  DNA/AdV  vaccination  [77]. 
Subsequent  studies  with  AdV  only-vaccinated  NHP  did  not  demonstrate  a  clear  correlation  with 
antigen-specific memory CD8+ or CD4+ T-cell cytokine expression and protection against EBOV 
infection [107]. Similarly, successful vaccination against MARV generated multiple cytokine-producing 
CD4+ and CD8+ T cells, but there was no clear correlation with the magnitude of memory T-cell 
generation and protection against clinical signs after challenge [108]. Vaccination against EBOV and 
SUDV did not generate detectable antibodies against BDBV, but did induce CD4+ and CD8+ T-cell 
responses against BDBV [79]. This was sufficient for protection against BDBV challenge, suggesting 
generation  of  memory  T  cells  may  possibly  be  sufficient  for  protection  [79].  Vaccination  with  a  
VSV-based vector expressing EBOV or MARV GP1,2 was protective in NHPs, but did not generate 
specific CD4+ or CD8+ T-cell responses [74]. Similarly, human parainfluenza virus type 3-based 
EBOV vaccines induced low to undetectable T-cell responses, yet still protect against infection [76]. 
Therefore, the available data suggest that that requirement of T cell subsets for effective protection 
against filovirus infection may differ depending on the vaccine platforms used to induce protection. 
Protection of unvaccinated individuals from filovirus infection may also heavily depend on both CD4+ 
and CD8+ T cells’ responses, although there is insufficient data to conclusively prove this hypothesis.  
2.5. NK Cells 
NK cells have been hypothesized to be important in controlling filovirus infection, since loss of 
peripheral NK cell numbers is found in lethally EBOV-infected NHPs [62], and NK cells are necessary 
for VLP vaccination against maEBOV infection in mice [109]. Furthermore, human NK cells activated 
with EBOV VLPs in vitro can kill EBOV- or MARV-infected DCs, and this cytotoxicity may occur 
via perforin or FasL and is partially reliant on the activating receptor NKp30 [110]. On the other hand, 
humans that survive EBOV infection were more likely to carry an ―activating‖ repertoire of the killer 
immunoglobulin-like receptor genes KIR2DS3 and KIR2DS1 when compared to those that succumb to 
infection  [111].  CD45
lo  mice  resistant  to  EBOV  infection,  however,  do  not  require  NK  cells  for Viruses 2011, 3                         
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protection [16]. NK cell activation is complex, and hinges on a complex interplay of activating and 
inhibitory  receptors.  Therefore,  it  is  still  uncertain  what  role  NK  cells  play  in  protection  against 
filovirus infection.  
2.6. HLA 
One  study  analyzed  human  leukocyte  antigen-B  (HLA-B)  alleles  in  77  humans  that  either 
succumbed  to  or  survived  SUDV  infection.  Survival  correlated  with  HLA-B*07  (11/11  infected 
individuals  carrying  this  allele  survived)  and  HLA-B-*14  (4/4  survivors),  while  HLA-B*67  
(0/8 survivors) and HLA-B*15 (4/17 survivors) alleles were associated with lethality [112]. This study 
suggests that the repertoire of antigen presentation on MHC I is an important factor in combating 
SUDV infection, further highlighting the possible importance of CD8+ T cells in filovirus infection. 
2.7. Macrophages and Dendritic Cells 
Alveolar macrophages infected in vitro with EBOV have decreased MHC I levels and increased  
IL-1beta, IL-6, IL-8, MIP-1 alpha, and TNF alpha production relative to mock-infected cells [113]. 
Similarly, monocytes infected in vitro with EBOV, MARV, or RESTV express increased TNF, IL-6, 
IL-8, and gro-alpha mRNA relative to mock-infected cells [114]. Macrophages and/or monocytes have 
been shown to be infected in vivo with TAFV, EBOV, MARV, and RESTV [12,64,115–119]. This 
conclusion was reached by the detection of inclusion bodies in and virus budding from these cells; the 
mere  detection  of  viral  RNA  or  antigen  is  not  sufficient  for  determination  of  viral  replication  in 
phagocytic cells since they can engulf previously infected cells and debris. 
Filoviruses  can  replicate  in  vitro  in  human  myeloid  dendritic  cells  (DCs).  EBOV  and  MARV 
infection  of  human  conventional  DCs  (cDC)  led  to  viral  replication,  but  not  secretion  of  IL-6, 
RANTES,  IL-10,  IL-1b,  IL-8,  IL-12,  or  IFN-alpha  [120].  Infection  also  inhibited  expression  of  
IFN-alpha  in  response  to  subsequent  VRP  infection  in  a  filoviral  replication-independent  manner. 
Inactivated MARV or EBOV treatment of DCs decreased allogeneic T-cell proliferation relative to 
mock-treated DC [120]. EBOV-infected DCs had decreased CD86, CD83, and HLA-DR expression 
compared to lipopolysaccharide (LPS)-treated cells, but still had increased levels of CD80 and CD86 
compared to mock-infected cells. A separate study also found EBOV replication in human myeloid 
DCs in vitro, and did not find increased levels of TNF-alpha, IL-6, IL-1b, IL-10, MIP-1 beta, although 
slight increases were found in IL-8, MIP-1a and MCP-1 relative to mock-infected cells [121]. CD40, 
CD80,  and  CD86  levels  were  similar  between  EBOV-infected  and  mock-infected  cells.  
EBOV-infected DCs were inhibited in their ability to induced allogeneic T-cell proliferation relative to 
LPS-treated DCs, but were still increased compared to mock-infected cells. In this study, however, 
inactivated EBOV-treated DCs were similar to mock-infected DCs in their ability to induce allogeneic 
T-cell proliferation.  
It is  important to  note  that  the  in  vitro  DC  experiments  described  above  were conducted with 
conventional DCs. A recent study suggested that plasmacytoid DC (pDC), which are major producers 
of type I IFN, are resistant to EBOV infection in vitro [122]. These data highlight the importance of 
studying different DC populations in attempting to explain the roles of these cells in filovirus infection. Viruses 2011, 3                         
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The  data  for  filoviral  infection  of  DC  in  vivo  is  scant.  One  study  described  detection  of  
EBOV  antigen  or  RNA  in  DCs  (as  identified  by  morphology  and  DC-SIGN  staining)  in  tissue  
sections from infected NHP [45]. There has been no analysis of DC subtypes or the frequency of DC 
infection in vivo. 
Together,  the  data  suggest  that  infectious  EBOV  or  MARV  do  not  increase  expression  of  
co-stimulatory markers or many pro-inflammatory cytokines in cDC, whereas infected macrophages 
do produce pro-inflammatory cytokines, at least in vitro. Infection of cDC with EBOV increased their 
ability to induce T-cell proliferation, but not to the level of LPS-stimulated cDC. However, there are 
not sufficient data to predict the overall effect of filovirus infection on cDC function. It does appear 
that infection of macrophages versus cDC may induce different cytokine responses in these cells [123]. 
2.8. Control of Viral Replication 
Most reports have shown that viremia is lower in non-fatal filoviral infection compared to fatal 
infection. This has been shown in humans that survive SUDV infection [54], mice or guinea pigs 
surviving EBOV infection after treatment with antivirals that inhibit replication [124,125], and guinea 
pigs or mice infected with lethal or non-lethal EBOV [11,12]. Similarly, mice infected with maRAVV 
had higher viral titers in sera and tissues compared to mice infected with wild-type RAVV [15]. A 
study showing decreased lethality in EBOV or MARV-infected NHP after administration of antisense 
against viral genes found that survival roughly correlated with decreased viral titer; however, some 
animals  that  survived  had  similar  peak  viremias  to  some  animals  that  succumbed  [9].  Similarly, 
resistant CD45
lo mice have similar viral titers through day 7 of maEBOV infection when compared to 
susceptible wild-type mice [16], and some antibody-treated guinea pigs that survive EBOV infection 
have similar viremias to some animals that succumb to infection [93]. These data indicate that viral 
replication by itself is not always a cause of pathogenesis; manipulation of cells to respond properly to 
viral infection may be as important as early control of viral replication. 
2.9. Gaps  
There are significant gaps in our knowledge of immune responses to filovirus infection. There are 
no data on immune responses to marburgvirus infection in humans. Genetic analysis of PMBC from 
humans that survived SUDV or EBOV infection versus those that succumbed has revealed possible 
links between HLA and KIR haplotypes and survival [111,112]. Given the advanced state of genome 
sequencing  technology,  broader  analysis  of  genetic  factors  should  be  performed  to  advance  the 
knowledge of correlates of immunity against filovirus infection.  
Development of immunological tools in filovirus infection is required to be able to answer more 
complex questions of filovirus immunity. The use of tetramers to detect antigen-specific T cells would 
greatly  aid  our  understanding  of  the  ability  of  different  vaccines  to  induce  T-cell  responses.  The 
creation of transgenic mice with filovirus-specific T or B cells would allow for more elegant studies of 
immune responses to filovirus infection. 
Transgenic and knockout mouse models are invaluable in testing correlates of immunity in filovirus 
vaccine platforms, as has been demonstrated in VLP vaccination [87]. The available data suggest that 
there are many different ways for the immune system to successfully combat filovirus infection. For Viruses 2011, 3                         
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example, different vaccine platforms generate different types of antibody and cell-mediated immune 
responses [8]. Other filoviral vaccine platforms should be tested in knockout and transgenic mice to 
discover  which  immune  pathways  are  required  for  protection.  Furthermore,  antibody-mediated 
depletion of immune cells and cytokines in vaccinated or drug-treated NHPs would shed light on the 
importance of immune components in filovirus infection in this model.  
There is no conclusive evidence that DCs are major targets for filoviral replication in vivo. Neither 
is there any data analyzing function of DCs or macrophages in vivo after infection. Although in vitro 
studies are important, in vivo studies are imperative for confirming how filoviruses affect macrophage 
and DC populations.  
As discussed above, there is conflicting data over whether or not passive transfer of convalescent 
sera or antibody can be protective in NHP or human filoviral infections. This is possibly due to the 
varied effectiveness of individual antibody preparations, the animal models used, the virus species, or a 
combination of these. Additional experiments in NHPs are crucial for exploring this topic. Further 
studies on how antibody  might protect (through neutralization, complement fixation, opsonization, 
ADCC,  etc.)  from  filovirus  infection  would  advance  understanding  of  the  feasibility  of  passive 
transfer. The possibility of using passive transfer to protect against filovirus infection is enticing, as it 
would provide a simple, well-characterized therapeutic platform for treatment.  
The use of mice resistant to EBOV infection (CD45
lo mice, mice infected s.c., or mice infected with 
wild-type  EBOV)  or  RAVV  infection  (wild-type  RAVV  versus  mouse-adapted  RAVV)  provide 
attractive models to compare successful versus unsuccessful immune responses to infection. Initial 
studies using these models have yielded information on immune responses in lethal versus non-lethal 
infections [11,15]. Further studies using these models would be helpful in generating information on 
immune response to filovirus infection. 
3. Conclusions  
The components required for successful immune responses to filovirus infection are likely to vary, 
depending on the virus strain and type of vaccination or therapeutic treatment. This is highlighted by 
the  varied  antibody  and  T  cell  responses  generated  in  different  protective  vaccination  platforms. 
Although there are currently not enough data for definitive conclusions, it appears that early, transient, 
and tightly regulated pro-inflammatory and type I IFN cytokine expression correlates with control of 
viral pathogenesis. MHC I and NK cell receptor genotyping suggests that genetic factors may also play 
a role in protection against filovirus infection. In vivo data on macrophage and DC infection and 
responses  to  filovirus  infection  are  lacking,  as  are  comparative  studies  on  immune  responses  to 
different filoviruses. The use of lethal and non-lethal animal models is invaluable to fill the gaps in our 
understanding of correlates of immunity to filovirus infection. 
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